Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.
Bhatt AP, Pellock SJ, Biernat KA, Walton WG, Wallace BD, Creekmore BC, Letertre MM, Swann JR, Wilson ID, Roques JR, Darr DB, Bailey ST, Montgomery SA, Roach JM, Azcarate-Peril MA, Sartor RB, Gharaibeh RZ, Bultman SJ, Redinbo MR.
Bhatt AP, et al. Among authors: roach jm.
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7374-7381. doi: 10.1073/pnas.1918095117. Epub 2020 Mar 13.
Proc Natl Acad Sci U S A. 2020.
PMID: 32170007
Free PMC article.